Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Price Controls: House Bill Flags Issue As Health Reform Moves Ahead

Executive Summary

A group of 61 House members is attempting to generate support for HHS drug price negotiations in Medicare Part D despite the fact that health care reform legislation is moving ahead in Congress without such a provision

You may also be interested in...



Obama Health Reform Plan Uses MA Cuts, Pharma Fees To Close Donut Hole

The Obama administration's proposal on health care reform would phase out the Medicare Part D coverage gap and pay for it through cuts to Medicare Advantage plans and with annual fees on branded biopharmaceutical companies

Closing Part D Gap May Be Among Senate Health Reform Bill Fixes

A plan to eliminate the Medicare Part D coverage gap is one of the measures House and Senate leaders continue to discuss as part of a package of changes to the Senate health reform bill that could be cleared through the budget reconciliation process, according to senior congressional staff

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel